NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $35.16 +0.27 (+0.77%) (As of 11:15 AM ET) Add Compare Share Share Today's Range$33.97▼$35.1650-Day Range$33.72▼$45.5452-Week Range$9.24▼$50.78Volume60,982 shsAverage Volume1.09 million shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$42.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vera Therapeutics alerts: Email Address Vera Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside22.8% Upside$42.86 Price TargetShort InterestBearish14.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 2 Articles This WeekInsider TradingSelling Shares$228,560 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.34) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.73 out of 5 starsMedical Sector827th out of 896 stocksPharmaceutical Preparations Industry390th out of 424 stocks 2.5 Analyst's Opinion Consensus RatingVera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVera Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Vera Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.71% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 0.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERA. Previous Next 1.4 News and Social Media Coverage News SentimentVera Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vera Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $228,560.00 in company stock.Percentage Held by Insiders21.70% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.34) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -17.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -17.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 17.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vera Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Vera Therapeutics Stock (NASDAQ:VERA)Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Read More VERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERA Stock News HeadlinesJune 30, 2024 | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Shares Up 3.6%June 11, 2024 | globenewswire.comVera Therapeutics Appoints Christy J. Oliger to Board of DirectorsJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.June 7, 2024 | globenewswire.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | globenewswire.comVera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 28, 2024 | markets.businessinsider.comVera Therapeutics Says FDA Grants Breakthrough Therapy Designation For Atacicept To Treat IgANMay 28, 2024 | globenewswire.comVera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)May 25, 2024 | globenewswire.comVera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association CongressJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics Amid Promising Clinical Developments and Strong Financial PositionMay 9, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024May 9, 2024 | msn.comVera Therapeutics GAAP EPS of -$0.56May 9, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | finance.yahoo.comVera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last weekMay 2, 2024 | markets.businessinsider.comIncyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales DipApril 14, 2024 | investing.comVera Therapeutics executive sells over $228k in company stockApril 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?See More Headlines Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/04/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERA CUSIPN/A CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$42.86 High Stock Price Target$68.00 Low Stock Price Target$25.00 Potential Upside/Downside+22.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.43% Return on Assets-39.06% Debt Debt-to-Equity Ratio0.14 Current Ratio28.63 Quick Ratio28.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book17.98Miscellaneous Outstanding Shares54,700,000Free Float42,831,000Market Cap$1.91 billion OptionableOptionable Beta1.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Marshall W. Fordyce M.D. (Age 49)Founder, President, CEO & Director Comp: $910.14kMr. Sean P. Grant M.B.A. (Age 39)Chief Financial Officer Comp: $642kMr. Joseph R. Young M.B.A. (Age 51)Senior VP of Finance & Chief Accounting Officer Mr. Julien E. Capers J.D.VP & Head of LegalMs. Kelly RauberVP & Head of Human ResourcesMr. Tom Doan (Age 52)Senior Vice President of Development Operations Ms. Lauren Frenz (Age 39)Chief Business Officer Dr. Neeraj Pakala M.B.A.Ph.D., Senior VP and Head of Product Development & ManufacturingDr. Kerry Cooper M.D.Senior Vice President of Medical AffairsDr. Robert M. Brenner M.D. (Age 56)Chief Medical Officer More ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVCerevel TherapeuticsNASDAQ:CEREIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsCambridge Trust Co.Bought 38,220 shares on 5/30/2024Ownership: 0.088%Cetera Advisors LLCBought 5,460 shares on 5/24/2024Ownership: 0.010%Virtu Financial LLCBought 8,704 shares on 5/20/2024Ownership: 0.016%Artal Group S.A.Bought 506,019 shares on 5/17/2024Ownership: 0.929%Jacobs Levy Equity Management Inc.Sold 275 shares on 5/16/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $15.38 at the start of the year. Since then, VERA stock has increased by 128.6% and is now trading at $35.16. View the best growth stocks for 2024 here. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.03. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERA) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
